MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs [Yahoo! Finance]
MiNK Therapeutics, Inc. (INKT)
Company Research
Source: Yahoo! Finance
Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Tuesday, March 31, 2026. The company will host a conference call and webcast at 8:30 a.m. ET that morning to review financial results and provide a corporate update on clinical progress, platform expansion, and strategic initiatives across its iNKT cell therapy portfolio. The update follows several recent corporate and development milestones, including MiNK's newly announced collaboration with C-Further and the University
Show less
Read more
Impact Snapshot
Event Time:
INKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INKT alerts
High impacting MiNK Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INKT
News
- MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy ProgramsGlobeNewswire
- MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers [Yahoo! Finance]Yahoo! Finance
- MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric CancersGlobeNewswire
- C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology [Yahoo! Finance]Yahoo! Finance
- C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric OncologyBusiness Wire
INKT
Earnings
- 11/14/25 - Beat
INKT
Sec Filings
- 3/23/26 - Form 3
- 3/19/26 - Form 8-K
- 3/11/26 - Form 4
- INKT's page on the SEC website